To resolve conflicting reports and provide a comprehensive survey of copy number alterations, allelic imbalances and transcriptional alterations in lung adenocarcinomas stratified by EGFR and KRAS mutation status, we analyzed 457 genomic and 914 gene expression profiles for differences between the three mutational groups (Figure 1). This evidence concerns the gene KRAS and lung adenocarcinoma.